Genetic Alterations Detected in Cell-Free DNA Are Associated With Enzalutamide and Abiraterone Resistance in Castration-Resistant Prostate Cancer.

JCO Precis Oncol · 2019 · PMC6532665 · PMID 31131348

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

did not reach statistical significanceno p-value reported

Prior abiraterone or enzalutamide exposure trended toward an association for worse outcomes, including PSA response (odds ratio [OR], 2.41; 95% CI, 0.74 to 7.93; P = .146), PFS (hazard ratio [HR], 1.17; 95% CI, 0.63 to 2.14; P = .620), and OS (HR, 1.51; 95% CI, 0.71 to 3.24; P = .284); however, these associations did not reach statistical significance ( Tables 2 and 3 and Data Supplement).

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.